GOOD NEWS! Phase I clinical trial results out of WashU Medicine show a first-of-its-kind personalized DNA vaccine designed to treat MGMT-unmethylated glioblastoma is safe AND elicits robust and broad immune responses that appears to INCREASE recurrence-free survival in patients after surgery.
Personalized DNA Vaccine Shows Immune Activation and Survival Signals in Glioblastoma Trial
Personalized neoantigen vaccine triggered immune responses and promising survival outcomes in MGMT-unmethylated glioblastoma Phase I trial patients.
insideprecisionmedicine.com